ReViral is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics, with an initial focus on the treatment of respiratory syncytial virus (RSV). The company’s lead product candidate, sisunatovir, is an orally administered fusion inhibitor currently being evaluated in two global Phase 2 clinical studies: one in a paediatric patient population and the other in an adult stem-cell transplant patient population. The company also has an N-protein replication inhibitor program in preclinical development.
.@ReViral_ltd's Head of Virology, Elaine Thomas, will be presenting #data from our #RSV program at the @isirvAVG meeting: 'COVID-19, Influenza & RSV: Surveillance-Informed Prevention & Treatment'. Poster 127 - 19 & 20 Oct 16:30 UK isirv.org/site/index.php #RSV #COVID19 #influenza pic.twitter.com/FDIO0sEcO5